BackAlzex Neuropharma Overview

Alzex Neuropharma Long Term Debt

Latest long-term debt for TRRI: $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Alzex Neuropharma Long Term Debt History

Loading

Alzex Neuropharma vs. peers: Long Term Debt Comparison

Loading

Alzex Neuropharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Alzex Neuropharma (TRRI) FAQ

Alzex Neuropharma (TRRI) currently reports a long-term debt of $0 as of June 2024. In the prior-year period, the figure was $0. Use the charts on this page to explore Alzex Neuropharma's long-term debt history and peer comparisons.

Alzex Neuropharma's long-term debt changed from $0 to $0 (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alzex Neuropharma reported $0 in long-term debt as of June 2024. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Alzex Neuropharma, and consider following TRRI for alerts when major investors trade the stock.